What is Aratana Therapeutics' stock symbol?
Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."
Where is Aratana Therapeutics' stock going? Where will Aratana Therapeutics' stock price be in 2017?
7 equities research analysts have issued twelve-month price targets for Aratana Therapeutics' stock. Their predictions range from $7.00 to $15.00. On average, they anticipate Aratana Therapeutics' share price to reach $10.50 in the next twelve months.
When will Aratana Therapeutics announce their earnings?
Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
What are analysts saying about Aratana Therapeutics stock?
Here are some recent quotes from research analysts about Aratana Therapeutics stock:
According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (2/9/2017)
- Stifel Nicolaus analysts commented, "Friday evening, Aratana announced that the launch of ENTYCE (capromorelin oral solution to treat inappetence for dogs) will be pushed out to late 2017 versus prior expectations of 1Q17. While the modest delay does not materially alter our peak sales expectations, it is the latest in a series of setbacks that have weighed on the company. In September 2015, Aratana's canine lymphoma initiative hit a meaningful roadblock, causing us to significantly curtail future sales expectations. More recently, a couple of other indications have taken longer to get to market due to resets with pilot studies (feline and AT-018), been de-prioritized (AT-007 feline immunodeficiency virus), or eliminated altogether (AT-011 canine parvovirus). The latest setback with ENTYCE is related to production/commercialization, and when combined with prior speed bumps, pushes the company's commercial sales traction out to 2018 (ENTYCE previously accounted for 75% of our 2017E sales). In our opinion, Aratana's story has subtly changed from that of revenue diversification (handful of drugs each accounting for 10-20% of sales) to one that is concentrated, with two drugs accounting for the majority of future sales. With this in mind, and the latest commercial setback which has now caused us to take a more conservative stance around the timeline for other indications, we downgrade to Hold (lower TP from $11 to $8) and wait for better visibility in the coming quarters (canine NOCITA and ENTYCE sales ramp, feline clinical initiatives)." (2/6/2017)
Who owns Aratana Therapeutics stock?
Aratana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (14.54%), Broadfin Capital LLC (9.98%), Janus Capital Management LLC (3.85%), State Street Corp (1.76%), First Light Asset Management LLC (1.11%) and Oxford Asset Management (0.67%). Company insiders that own Aratana Therapeutics stock include Craig A Tooman, Ernst Heinen, Julia A Stephanus, Linda Rhodes, Peter Steven St and Vort John Vander.
Who sold Aratana Therapeutics stock? Who is selling Aratana Therapeutics stock?
Aratana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Turner Investments LLC, First Light Asset Management LLC, Wall Street Associates, Oxford Asset Management, Numeric Investors LLC, State Street Corp, Renaissance Technologies LLC and Franklin Resources Inc.. Company insiders that have sold Aratana Therapeutics stock in the last year include Craig A Tooman, Ernst Heinen, Julia A Stephanus and Peter Steven St.
Who bought Aratana Therapeutics stock? Who is buying Aratana Therapeutics stock?
Aratana Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Broadfin Capital LLC, Dimensional Fund Advisors LP, AQR Capital Management LLC, A.R.T. Advisors LLC, Cadence Capital Management LLC, Baird Financial Group Inc. and Redmond Asset Management LLC.
How do I buy Aratana Therapeutics stock?
Shares of Aratana Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Aratana Therapeutics stock cost?
One share of Aratana Therapeutics stock can currently be purchased for approximately $6.50.